Redwood Investment Management LLC purchased a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 4,652 shares of the company’s stock, valued at approximately $642,000.
Other institutional investors have also recently added to or reduced their stakes in the company. RFP Financial Group LLC raised its stake in shares of Neurocrine Biosciences by 346.5% in the first quarter. RFP Financial Group LLC now owns 192 shares of the company’s stock worth $26,000 after acquiring an additional 149 shares during the last quarter. Mather Group LLC. bought a new stake in shares of Neurocrine Biosciences during the first quarter worth approximately $26,000. Lindbrook Capital LLC raised its stake in shares of Neurocrine Biosciences by 85.0% during the fourth quarter. Lindbrook Capital LLC now owns 209 shares of the company’s stock worth $28,000 after buying an additional 96 shares during the last quarter. EdgeRock Capital LLC bought a new stake in shares of Neurocrine Biosciences during the fourth quarter worth approximately $31,000. Finally, Benjamin F. Edwards & Company Inc. bought a new stake in shares of Neurocrine Biosciences during the fourth quarter worth approximately $33,000. 92.59% of the stock is owned by institutional investors.
Insider Activity
In other Neurocrine Biosciences news, Director Stephen A. Sherwin sold 40,000 shares of the firm’s stock in a transaction dated Wednesday, May 29th. The shares were sold at an average price of $133.46, for a total value of $5,338,400.00. Following the completion of the sale, the director now directly owns 26,504 shares in the company, valued at $3,537,223.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Stephen A. Sherwin sold 40,000 shares of the business’s stock in a transaction on Wednesday, May 29th. The shares were sold at an average price of $133.46, for a total transaction of $5,338,400.00. Following the completion of the sale, the director now owns 26,504 shares of the company’s stock, valued at approximately $3,537,223.84. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Matt Abernethy sold 15,000 shares of Neurocrine Biosciences stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $140.24, for a total transaction of $2,103,600.00. Following the transaction, the chief financial officer now owns 31,528 shares in the company, valued at approximately $4,421,486.72. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 80,709 shares of company stock valued at $11,009,150. 4.30% of the stock is currently owned by company insiders.
Analyst Ratings Changes
Read Our Latest Stock Analysis on NBIX
Neurocrine Biosciences Price Performance
Shares of NBIX traded up $8.98 during mid-day trading on Thursday, hitting $150.55. The stock had a trading volume of 454,616 shares, compared to its average volume of 815,195. The business has a fifty day moving average price of $139.29 and a 200-day moving average price of $138.16. Neurocrine Biosciences, Inc. has a 52 week low of $100.52 and a 52 week high of $157.98. The firm has a market cap of $15.15 billion, a P/E ratio of 42.30 and a beta of 0.37.
Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) last released its quarterly earnings results on Wednesday, May 1st. The company reported $0.42 earnings per share for the quarter, missing the consensus estimate of $1.04 by ($0.62). Neurocrine Biosciences had a return on equity of 17.45% and a net margin of 18.65%. The firm had revenue of $515.30 million during the quarter, compared to the consensus estimate of $512.21 million. As a group, research analysts expect that Neurocrine Biosciences, Inc. will post 4.22 earnings per share for the current fiscal year.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Read More
- Five stocks we like better than Neurocrine Biosciences
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Mastercard Stock’s Q2 Financial Results Outshine Competitors
- High Flyers: 3 Natural Gas Stocks for March 2022
- Tobacco Giant’s Shares Fall on EPS Miss, Lackluster Pouch Gains
- Bank Stocks – Best Bank Stocks to Invest In
- Analysts Expect At Least 60% Upside In This Fintech
Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report).
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.